Leukocyte Expression Linked with Penile Cancer Outcomes

Share this content:
HLA expression appears to be tied to clinical outcomes in penile cancer.
HLA expression appears to be tied to clinical outcomes in penile cancer.

Human leukocyte antigen (HLA) expression appears to be tied to clinical outcomes in penile cancer, according to a study published in The Journal of Urology.

Rosa S. Djajadiningrat, M.D., from the Netherlands Cancer Institute in Amsterdam, and colleagues constructed tissue microarrays from penile cancer tissue blocks from 168 patients who underwent surgical resection between 2000 and 2009.

HLA expression was determined using immunohistochemical staining (using classic and nonclassic molecules), and expression was scored semiquantitatively.

The researchers found that complete and partial loss of total classic HLA class I were seen in 32 and 50 percent of cases, respectively. Up-regulation of HLA-E and G was seen in 16 and 13 percent, respectively.

RELATED: High-Risk HPV Present in Subset of Penile Carcinomas

Partial HLA-A loss was significantly associated with decreased survival overall (hazard ratio, 2.3) and in human papillomavirus-negative patients alone (hazard ratio, 3.4), when adjusting for relevant clinical parameters. Survival was not tied to abnormal HLA-B/C, E, or G expression levels.

"Complete understanding of the mechanisms and relevance of HLA down-regulation and immune evasion in regard to the clinical outcome will contribute to the future design of immunotherapy interventions," the authors write.

Reference

  1. Djajindinigrat, Rosa S., et al. "Classic and Nonclassic HLA Class I Expression in Penile Cancer and Relation to HPV Status and Clinical Outcome." The Journal of Urology. DOI: http://dx.doi.org/10.1016/j.juro.2014.11.057. November 14, 2014.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters